AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
valbenazine š¶ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5227 | 1025504-45-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 1.31 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 18 hours | Lombardo F, Berellini G, Obach RS |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,IGF1R,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 | 42 | |||
| kinase-selectivity-class | AXL,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 11, 2017 | FDA | NEUROCRINE BIOSCIENCES INC | |
| March 28, 2022 | PMDA | Mitsubishi Tanabe Pharma Corporation |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Somnolence | 660.09 | 36.11 | 330 | 7330 | 208754 | 90412033 |
| Drooling | 652.04 | 36.11 | 134 | 7526 | 4412 | 90616375 |
| Parkinsonism | 588.03 | 36.11 | 152 | 7508 | 13913 | 90606874 |
| Tremor | 509.82 | 36.11 | 251 | 7409 | 152922 | 90467865 |
| Dyskinesia | 334.25 | 36.11 | 123 | 7537 | 36411 | 90584376 |
| Sedation | 308.07 | 36.11 | 125 | 7535 | 48046 | 90572741 |
| Akathisia | 177.94 | 36.11 | 57 | 7603 | 11102 | 90609685 |
| Hospitalisation | 165.90 | 36.11 | 114 | 7546 | 127986 | 90492801 |
| Death | 161.12 | 36.11 | 195 | 7465 | 456356 | 90164431 |
| Tardive dyskinesia | 142.69 | 36.11 | 48 | 7612 | 10882 | 90609905 |
| Fall | 140.18 | 36.11 | 187 | 7473 | 481623 | 90139164 |
| Therapeutic product effect decreased | 139.88 | 36.11 | 143 | 7517 | 277428 | 90343359 |
| Balance disorder | 127.03 | 36.11 | 87 | 7573 | 96993 | 90523794 |
| Restlessness | 110.75 | 36.11 | 56 | 7604 | 35664 | 90585123 |
| Drug ineffective | 102.69 | 36.11 | 301 | 7359 | 1383997 | 89236790 |
| Adverse drug reaction | 95.54 | 36.11 | 79 | 7581 | 116622 | 90504165 |
| Anxiety | 87.92 | 36.11 | 119 | 7541 | 309653 | 90311134 |
| Suicidal ideation | 86.79 | 36.11 | 62 | 7598 | 73793 | 90546994 |
| Feeling abnormal | 81.96 | 36.11 | 85 | 7575 | 167150 | 90453637 |
| Dizziness | 73.82 | 36.11 | 157 | 7503 | 589127 | 90031660 |
| Bipolar disorder | 70.22 | 36.11 | 27 | 7633 | 8958 | 90611829 |
| Depression | 69.81 | 36.11 | 105 | 7555 | 300496 | 90320291 |
| Salivary hypersecretion | 66.37 | 36.11 | 26 | 7634 | 9066 | 90611721 |
| Lethargy | 62.89 | 36.11 | 48 | 7612 | 63091 | 90557696 |
| Therapeutic product effect incomplete | 60.33 | 36.11 | 78 | 7582 | 193818 | 90426969 |
| Bradykinesia | 58.83 | 36.11 | 22 | 7638 | 6766 | 90614021 |
| Nightmare | 58.51 | 36.11 | 31 | 7629 | 21694 | 90599093 |
| Urticaria | 51.99 | 36.11 | 94 | 7566 | 312640 | 90308147 |
| Gait disturbance | 49.40 | 36.11 | 83 | 7577 | 260413 | 90360374 |
| Agitation | 45.86 | 36.11 | 41 | 7619 | 67057 | 90553730 |
| Dystonia | 42.48 | 36.11 | 23 | 7637 | 16796 | 90603991 |
| Fatigue | 41.12 | 36.11 | 199 | 7461 | 1153824 | 89466963 |
| Tic | 39.87 | 36.11 | 12 | 7648 | 1899 | 90618888 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drooling | 570.12 | 40.58 | 120 | 3735 | 4179 | 42613301 |
| Parkinsonism | 357.44 | 40.58 | 98 | 3757 | 10525 | 42606955 |
| Somnolence | 310.13 | 40.58 | 179 | 3676 | 140926 | 42476554 |
| Tremor | 244.99 | 40.58 | 135 | 3720 | 96794 | 42520686 |
| Sedation | 166.30 | 40.58 | 72 | 3783 | 30403 | 42587077 |
| Hospitalisation | 133.09 | 40.58 | 83 | 3772 | 74247 | 42543233 |
| Dyskinesia | 125.54 | 40.58 | 56 | 3799 | 25334 | 42592146 |
| Therapeutic product effect decreased | 116.61 | 40.58 | 61 | 3794 | 39089 | 42578391 |
| Anxiety | 90.10 | 40.58 | 79 | 3776 | 118481 | 42498999 |
| Suicidal ideation | 79.11 | 40.58 | 51 | 3804 | 48110 | 42569370 |
| Fall | 78.67 | 40.58 | 101 | 3754 | 234419 | 42383061 |
| Adverse drug reaction | 77.64 | 40.58 | 46 | 3809 | 37388 | 42580092 |
| Restlessness | 74.21 | 40.58 | 41 | 3814 | 29208 | 42588272 |
| Drug ineffective | 73.35 | 40.58 | 169 | 3686 | 630028 | 41987452 |
| Death | 69.17 | 40.58 | 139 | 3716 | 471046 | 42146434 |
| Balance disorder | 55.85 | 40.58 | 41 | 3814 | 47604 | 42569876 |
| Akathisia | 54.64 | 40.58 | 24 | 3831 | 10427 | 42607053 |
| Dizziness | 53.58 | 40.58 | 87 | 3768 | 249167 | 42368313 |
| Agitation | 45.04 | 40.58 | 41 | 3814 | 64273 | 42553207 |
| Lethargy | 43.23 | 40.58 | 35 | 3820 | 46855 | 42570625 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drooling | 623.05 | 37.63 | 135 | 7577 | 7004 | 110574583 |
| Parkinsonism | 562.16 | 37.63 | 155 | 7557 | 22032 | 110559555 |
| Somnolence | 540.94 | 37.63 | 305 | 7407 | 297144 | 110284443 |
| Tremor | 474.94 | 37.63 | 246 | 7466 | 201986 | 110379601 |
| Dyskinesia | 281.21 | 37.63 | 113 | 7599 | 51333 | 110530254 |
| Sedation | 254.51 | 37.63 | 115 | 7597 | 69568 | 110512019 |
| Death | 208.50 | 37.63 | 249 | 7463 | 698620 | 109882967 |
| Hospitalisation | 197.23 | 37.63 | 123 | 7589 | 142370 | 110439217 |
| Fall | 157.03 | 37.63 | 201 | 7511 | 603281 | 109978306 |
| Anxiety | 138.63 | 37.63 | 144 | 7568 | 344934 | 110236653 |
| Tardive dyskinesia | 133.70 | 37.63 | 46 | 7666 | 13533 | 110568054 |
| Restlessness | 133.04 | 37.63 | 69 | 7643 | 56190 | 110525397 |
| Akathisia | 116.04 | 37.63 | 44 | 7668 | 17069 | 110564518 |
| Balance disorder | 116.02 | 37.63 | 82 | 7630 | 116478 | 110465109 |
| Suicidal ideation | 100.27 | 37.63 | 69 | 7643 | 93868 | 110487719 |
| Therapeutic product effect decreased | 87.42 | 37.63 | 96 | 7616 | 244220 | 110337367 |
| Feeling abnormal | 77.06 | 37.63 | 78 | 7634 | 180633 | 110400954 |
| Lethargy | 75.41 | 37.63 | 58 | 7654 | 93518 | 110488069 |
| Depression | 71.84 | 37.63 | 99 | 7613 | 317236 | 110264351 |
| Dizziness | 68.14 | 37.63 | 150 | 7562 | 698043 | 109883544 |
| Adverse drug reaction | 67.19 | 37.63 | 57 | 7655 | 105502 | 110476085 |
| Salivary hypersecretion | 64.27 | 37.63 | 29 | 7683 | 17392 | 110564195 |
| Gait disturbance | 63.25 | 37.63 | 87 | 7625 | 278121 | 110303466 |
| Urticaria | 58.37 | 37.63 | 90 | 7622 | 318767 | 110262820 |
| Fatigue | 51.30 | 37.63 | 193 | 7519 | 1215765 | 109365822 |
| Drug ineffective | 51.24 | 37.63 | 225 | 7487 | 1520315 | 109061272 |
| Agitation | 48.52 | 37.63 | 49 | 7663 | 113002 | 110468585 |
| Dystonia | 47.97 | 37.63 | 27 | 7685 | 25778 | 110555809 |
| Therapeutic product effect incomplete | 46.40 | 37.63 | 67 | 7645 | 223738 | 110357849 |
| Bradykinesia | 46.38 | 37.63 | 20 | 7692 | 10768 | 110570819 |
| Bipolar disorder | 39.72 | 37.63 | 17 | 7695 | 8990 | 110572597 |
| Insomnia | 39.10 | 37.63 | 81 | 7631 | 360509 | 110221078 |
| Depressed mood | 39.00 | 37.63 | 33 | 7679 | 60776 | 110520811 |
| Nightmare | 37.82 | 37.63 | 27 | 7685 | 38836 | 110542751 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07XX13 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
| FDA MoA | N0000190855 | Vesicular Monoamine Transporter 2 Inhibitors |
| FDA EPC | N0000190856 | Vesicular Monoamine Transporter 2 Inhibitor |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
Related Drugs by ATC class:
N07XX Other nervous system drugs 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tardive dyskinesia | indication | 102449007 |
š¶ Veterinary Drug Use
None
š¶ Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.25 | Basic |
| pKa2 | 7.56 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11439629 | Oct. 10, 2037 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11654142 | Nov. 14, 2038 | A METHOD OF TREATING HUNTINGTONS CHOREA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONāS DISEASE |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONāS DISEASE |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONāS DISEASE |
| EQ 40MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONāS DISEASE |
| EQ 60MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONāS DISEASE |
| EQ 80MG BASE | INGREZZA SPRINKLE | NEUROCRINE | N218390 | April 30, 2024 | RX | CAPSULE | ORAL | Aug. 18, 2026 | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONāS DISEASE |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | Aug. 18, 2030 | FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | Aug. 18, 2030 | FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | Aug. 18, 2030 | FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 8.52 | DRUG LABEL | DRUG LABEL | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.77 | CHEMBL | |||||
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 6.73 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 54K37P50KH | UNII |
| 1639208-54-0 | SECONDARY_CAS_RN |
| 4036639 | VANDF |
| C4078701 | UMLSCUI |
| CHEBI:754993 | CHEBI |
| XW7 | PDB_CHEM_ID |
| CHEMBL2364639 | ChEMBL_ID |
| 24795069 | PUBCHEM_CID |
| DB11915 | DRUGBANK_ID |
| D10675 | KEGG_DRUG |
| CHEMBL3707248 | ChEMBL_ID |
| 9744 | INN_ID |
| C000603978 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8694 | IUPHAR_LIGAND_ID |
| 733727001 | SNOMEDCT_US |
| 763512007 | SNOMEDCT_US |
| 255701 | MMSL |
| 32624 | MMSL |
| d08559 | MMSL |
| 14580381 | PUBCHEM_CID |
| 017167 | NDDF |
| 017168 | NDDF |
| 1918219 | RXNORM |
| 54K37P50KH | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 33 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4040 | CAPSULE | 40 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4040 | CAPSULE | 40 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4060 | CAPSULE | 60 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4060 | CAPSULE | 60 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4080 | CAPSULE | 80 mg | ORAL | NDA | 33 sections |
| INGREZZA Sprinkle | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-4080 | CAPSULE | 80 mg | ORAL | NDA | 33 sections |